# Quinn Bio — Your biopharma team

Quinn is a team companies engage for research, data analysis and computational design. It carries out complete pieces of scientific and strategic work across discovery and development, portfolio investment, commercial strategy, manufacturing, regulatory work and medical affairs.

## Engagement

1. Describe your work: say what your team is working on and what it needs to figure out.
2. Review the plan: review the proposed scope and deliverables; request changes before work begins.
3. Receive your report: the comprehensive report and supporting work arrive in 3–5 days after approval of the work. Discuss the findings, implications and next steps.

Every run delivers a comprehensive report: an executive summary followed by detailed sections covering the findings, options, comparisons, risks and recommendations, with the supporting research, evidence and analysis. Figures, tables, models, computational designs, methods and reproducible code are provided as relevant to the project. The report distinguishes supported findings, uncertainty and proposed next work.

## Capabilities

- Research and discovery: targets, mechanisms, omics, structure-based chemistry and computational molecule/protein design.
- Translational science: biomarkers, patient selection, human translation, PK/PD and evidence planning.
- Clinical development: trial and statistical design, population and dose strategy, simulations where supported, and development planning.
- Safety: mechanistic safety, benefit–risk, toxicology, postmarketing signals and risk management.
- Portfolio and commercial strategy: portfolio prioritization, resource allocation, asset valuation, due diligence, licensing, acquisition, partnering, pricing, market access, launch and lifecycle strategy.
- CMC and regulatory: process/formulation analysis, manufacturing economics, supply strategy, regulatory pathways and submission support.
- Medical affairs: evidence generation, scientific communication, health economics, medical launch and access evidence.

Quinn carries out research, computation, design and strategic work. Clients and their partners conduct physical experiments, clinical operations and manufacturing.

## Selected work

An independent assessment using public evidence through August 2026 considered population, formulation and competitive positioning for TQC3721 in COPD. The reviewed evidence did not support selecting between two leading populations or choosing a lead formulation. The assessment identified what a prospective study would need to resolve. It is not a sponsor endorsement or an observed clinical outcome.

## People and data

Founders: Daniel Gomari, PhD, and Michael Snyder, PhD. Snyder is Professor of Genetics and Director of the Center for Genomics and Personalized Medicine at Stanford, and a former department chair (2009–2024).

Quinn Bio is a service of iollo, Inc. Client IP remains the client's. Project data is not used to train models. Data access, handling and retention are agreed for the engagement.

## Canonical destinations

https://www.quinnbio.com/
https://www.quinnbio.com/capabilities
https://www.quinnbio.com/case-studies
https://www.quinnbio.com/methodology
https://www.quinnbio.com/team
https://www.quinnbio.com/security
https://www.quinnbio.com/#contact

Inquiries: team@quinnbio.com

A Quinn run is one defined piece of work. Clients can ask follow-up questions alongside the results.
Security assurance: iollo holds ISO/IEC 27001:2022 certification and a SOC 2 Type II report covering Quinn. A HIPAA business associate agreement is available where required.